ENAVATE SCIENCES GP, LLC
CIK 1953107 · View on SEC EDGAR ↗
- Portfolio value
- $345.4M
- Positions
- 7
- As of
- June 30, 2026
Portfolio value QoQ: -1.7% 13F does not disclose cash
- Top 10 holdings weight
- 100.00%
- Top 25 holdings weight
- 100.00%
- Positions above 1%
- 7
- Effective number of positions
- 4.2
Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)
Turnover Q2 2026: 0.0% Est. buys $0 · sells $3,344,706
Median holding: 7.0 quarters Tracked Q4 2024–Q2 2026 · 100.0% still held
- New positions
- 0
- Increased
- 0
- Decreased
- 1
- Closed
- 0
On this page
- Performance vs S&P How this manager's 13F portfolio performed against the S&P 500.
- Sector breakdown How the portfolio splits across market sectors.
- Portfolio Every stock this institution reports holding, from its latest 13F.
- Top moves The biggest position increases and decreases this quarter.
- Related The person behind this filer, where we can match one.
Performance vs S&P 500
Annualized: +48.9% · S&P 500: +18.0%
Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.
Priceable coverage: 100.0% · Options excluded: 0.0%
Sector breakdown
Full portfolio 7 positions
| Type | Streak | 8Q trend | |||||
|---|---|---|---|---|---|---|---|
| SION Sionna Therapeutics, Inc. - Common Stock | $109,008,540 | 31.56% | 2,478,030 | $9,664,317 | |||
| ZBIO Zenas BioPharma, Inc. - Common Stock | $99,468,255 | 28.80% | 3,919,159 | $22,848,697 | |||
| IMNM Immunome, Inc. - Common Stock | $76,576,401 | 22.17% | 3,613,799 | $-2,457,383 | |||
| BBOT BridgeBio Oncology Therapeutics, Inc. - Common Stock | $20,017,329 | 5.80% | 2,626,946 | $-3,493,838 | |||
| CMPX Compass Therapeutics, Inc. - Common Stock | $17,056,049 | 4.94% | 7,788,150 | $-24,143,265 | |||
| UPB Upstream Bio, Inc. - Common Stock | $17,021,145 | 4.93% | 2,459,703 | $-5,116,182 | |||
| CAMP CAMP4 Therapeutics Corporation - Common Stock | $6,229,614 | 1.80% | 1,425,541 | $-3,432,343 | Down ×3 | ||
| No matches | |||||||